[c09aa8]: / clusters / 9knumclustersv2 / clust_845.txt

Download this file

157 lines (156 with data), 13.2 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
History of congestive heart failure
No congestive heart failure (CHF) within days of registration
History of congestive heart failure or myocardial infarction < year prior to first study dose administration
Active congestive heart failure or ventricular arrhythmia requiring medication
Congestive heart failure
History of active myocardial ischemia, cardiomyopathy, uncontrolled dysrhythmia, or congestive heart failure within the last months before enrollment
Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months
Symptomatic congestive heart failure
History of myocardial infarction or decompensated congestive heart failure (CHF) within the last months
Congestive heart failure (CHF) since axitinib can cause CHF
History of pulmonary edema or decompensated congestive heart failure with in six () week of enrollment.
History or presence of myocardial infarction, clinically relevant valvular heart disease, or congestive heart failure within the last months;
Symptoms of congestive heart failure or uncontrolled cardiac rhythm disturbance
Current symptomatic congestive heart failure or history of symptomatic congestive heart failure in the preceding months, defined as New York (NY) Heart Association classification -
Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the investigator (e.g., uncontrolled congestive heart failure, active infection, etc.);
Patients with history of congestive heart failure stage III or greater
For participants with congestive heart failure, cardiovascular-related hospitalizations within weeks prior to randomization
Patients with history of congestive heart failure stage III or greater
Symptomatic congestive heart failure
Been treated with appropriate maximal medical therapy for heart failure
Patients with history of congestive heart failure are excluded
Unstable angina and/or congestive heart failure requiring hospitalization within the last months
Subject with significant congestive heart failure (CHF) or history of CHF, chronic renal failure, hepatic failure, neuropathy
Significant history of a medical problem or co-morbidity that would preclude the patient from undergoing a major abdominal operation such as a history of severe congestive heart failure or active ischemic heart disease
Previous hospitalization due to documented heart failure in the last months
Congestive heart failure < months prior to screening
Presence of a symptomatic bradyarrhythmia or uncompensated heart failure
Congestive heart disease not controlled by medication.
Congestive heart failure (CHF) within months prior to first dose;
No acute congestive heart failure
Uncontrolled congestive heart failure or angina
Subjects with uncontrolled (over the last days) clinically significant confounding medical conditions such as congestive heart failure
Current clinical heart failure or symptomatic ischemic heart disease
History of myocardial infarction =< months, or current symptomatic congestive heart failure or left ventricular ejection fraction (LVEF) < % or with > grade diastolic dysfunction, with no symptoms or signs of heart failure
Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months
Congestive heart failure requiring medication (other than diuretic)
Uncontrolled ischemic heart disease, or uncontrolled symptomatic congestive heart failure
Active ischemic heart disease or congestive heart failure
Been treated with appropriate maximal medical therapy for heart failure
Subjects with clinically significant active ischemic heart disease, cardiac muscle disease (including cardiomyopathy or congestive heart failure) or myodegenerative disorders that may affect safe study participation
Unstable angina and/or congestive heart failure requiring hospitalization within months prior to step registration
Serious intercurrent medical illness (e.g., symptomatic congestive heart failure)
Has a history of significant congestive heart failure or significant pulmonary disease
Within days of registration: Absence of clinical decompensated congestive heart failure or uncontrolled arrhythmia
Symptomatic congestive heart failure (CHF)
Absence of clinically significant cardiomyopathy, congestive heart failure
No decompensated congestive heart failure (CHF), or uncontrolled arrhythmia; ejection fraction (EF) >= %
Absence of clinically significant cardiomyopathy, congestive heart failure
Previous history of congestive heart failure
Cerebrovascular or cardiovascular event, or congestive heart failure within the last months.
Active congestive heart failure or ventricular arrhythmia requiring medication
Significant cardiovascular disease (including congestive heart failure).
Unstable angina and/or congestive heart failure requiring hospitalization within the last months
No congestive heart failure < months
Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure
Echocardiogram (ECHO) cardiogram and cardiology consultation required within days prior to registration for patients with a history of congestive heart failure or cardiovascular disease or history of exposure to cardiotoxic agents who are not already excluded
Known active symptomatic congestive heart failure
Patients with symptoms of congestive heart failure are not eligible
No Symptomatic Congestive Heart Failure (Ejection Fraction EF ? %)
Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure
History of congestive heart failure or other findings of ventricular dysfunction
Symptomatic congestive heart failure
Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure
The participant has symptomatic congestive heart failure (CHF), left ventricular dysfunction (LVEF < %), severe myocardial insufficiency, cardiac arrhythmia, or cardiomyopathy.
Known congestive heart failure requiring medical management
History of congestive heart failure or systolic dysfunction (LVEF <%)
History of symptomatic congestive heart failure within months prior to the initiation of therapy on this protocol
Congestive heart failure (CHF) within months prior to first dose
Evidence of uncontrolled congestive heart failure
Symptomatic congestive heart failure
History of congestive heart failure (CHF)
Has symptomatic congestive heart failure (CHF)
The patient has a history of uncontrolled angina, arrhythmias, or congestive heart failure
Patients must not have unstable angina or NYHA classification of congestive heart failure of grade >=
No decompensated congestive heart failure (CHF), or uncontrolled arrhythmia
Uncompensated congestive heart failure
Grade or greater congestive heart failure
History of hospitalization for Congestive Heart Failure
History of heart disease
History of heart disease.
Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible
Severe cardiovascular disease, i.e., arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease
Patients cannot have known cardiac disease (either arrhythmia or congestive heart failure) requiring treatment
Clinically significant and/or uncontrolled heart disease such as congestive heart failure (CHF) requiring treatment (NYH grade ?), hypertension or arrhythmia
Serious intercurrent medical illness (e.g., symptomatic congestive heart failure)
Patients with congestive heart failure or significant arrhythmia
Has a medical history of symptomatic Congestive Heart Failure (CHF) (NYHA classes II-IV) or serious cardiac arrhythmia.
Symptomatic congestive heart failure
Uncontrolled arrhythmia or heart failure
Congestive heart failure.
History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
History of congestive heart failure;
Patients with history of congestive heart failure
Symptomatic congestive heart failure
History of congestive heart failure (CHF)
Active symptomatic congestive heart failure
Congestive heart failure (CHF) currently requiring therapy
Active congestive heart failure or ventricular arrhythmia
Symptomatic congestive heart failure;
Congestive heart failure (CHF) currently requiring therapy
No evidence of clinically significant congestive heart failure, (ejection fraction of % or greater)
Has an active infection, congestive heart failure, slow heart rate, or other uncontrolled disease other than cancer
Active heart disease
Unstable congestive heart failure
History or current symptoms of congestive heart failure (shortness of breath, ankle swelling)
Clinical diagnosis of congestive heart failure and/or pulmonary capillary wedge pressure > mmHg, or uncorrected congenital heart disease.
Congestive heart failure,
Unstable angina or uncontrolled congestive heart failure
Active symptomatic congestive heart failure
Congestive heart failure requiring medication (other than diuretic)
Heart failure exacerbation at the time of study enrollment.
History of or active ventricular dysrhythmias or congestive heart failure requiring medication or symptomatic coronary heart disease
Unstable angina and/or congestive heart failure requiring hospitalization within the last months prior to registration.
Extremity edema due to heart failure
Patients with history of congestive heart failure
Uncontrolled heart failure in the last week
Congestive heart failure
Congestive heart failure
Receiving treatment for cardiomyopathy or congestive heart failure
History of congestive heart failure and ejection fraction less than %
History of congestive heart failure; systolic heart failure defined as ejection fraction (EF) =< %, or diastolic heart failure defined as EF > % PLUS systemic manifestation of heart failure
Congestive heart failure (CHF)
Patients with history of congestive heart failure
Congestive heart failure or documented cardiomyopathy with an EF ?%, provided that EF ?% or,
No significant history of a medical problem or co-morbidity that would preclude the patient from undergoing a major abdominal operation such as a history of severe congestive heart failure or active ischemic heart disease
Unstable angina or uncontrolled congestive heart failure
Documentation of congestive heart failure and ejection fraction < % if recorded in the pre-operative record
Heart failure exacerbation at the time of enrollment
Heart failure exacerbation at the time of study enrollment
Any patient with known ischemic heart disease, history of congestive heart failure, history of stroke, or cardiac arrhythmia for which the patient requires medication or a medical device
Congestive heart failure refractory to medical management
Receiving treatment for cardiomyopathy or heart failure
NYHA stage or congestive heart failure
Known heart disease
Known heart disease
History of myocardial disease, such as myocarditis, cardiomyopathy, congestive heart failure, ischemic cardiomyopathy
Patients with congestive heart failure requiring pharmacological management
Participant reported history of congestive heart failure
Congestive heart failure
Liver impairment or congestive heart failure
Has an active infection (e.g., pneumonia), congestive heart failure, bradyarrhythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) except for malignancy
congestive heart failure
uncontrolled symptomatic heart failure,
History of renal disease, hypertension, diabetes, congestive heart failure or emphysema
> stage heart failure
Worsening of or clinically unstable congestive heart failure
Congestive heart failure, clinically significant
History of congestive heart failure
History of clinically significant congestive heart failure
Participants with history of hypertension, congestive heart failure, edema, stroke or other cardiac disease or condition
Patients with history of congestive heart failure
Symptomatic congestive heart failure.
Men who have contraindications to exercise based the American College of Sports Medicine Exercise pre-participation screening criteria and who do not receive a physician clearance to participate in the moderate intensity physical activity with one or more of the following self-reported conditions:\r\n* heart attack\r\n* heart surgery, cardiac catherization, or coronary angioplasty\r\n* pacemaker/implantable cardiac defibrillator/rhythm disturbance\r\n* heart valve disease \r\n* heart failure \r\n* heart transplantation \r\n* congenital heart disease \r\n* diabetes \r\n* kidney (renal) disease\r\n* chest discomfort with exertion \r\n* unreasonable breathlessness \r\n* dizziness, fainting or blackouts \r\n* ankle swelling \r\n* unpleasant awareness of forceful, rapid or irregular heart rate \r\n* burning or cramping sensations in your lower legs when walking short distance
Other clinically significant heart disease (e.g. congestive heart failure, cardiomyopathy or uncontrolled hypertension)
Unstable angina and/or congestive heart failure requiring hospitalization within the last months
History of heart disease